The study assessed the T-cell subsets and their activation via peripheral blood flow cytometry in patients before and during treatment to analyze the tumor immunity-modulatory effect of prexasertib combined with LY3300054, and observed CD8+T-cell activation. Here, CD8A is linked to neoplasm.